A comparative study of the two leadless pacemakers in clinical practice

Author:

Shantha Ghanshyam1ORCID,Brock Jonathan1,Singleton Matthew J.2,Schmitt Alexander Joseph3,Kozak Patrick1,Bodziock George1,Bradford Natalie1,Whalen Patrick1,Bhave Prashant1ORCID

Affiliation:

1. Cardiac Electrophysiology Wake Forest University Winston‐Salem North Carolina USA

2. Wellspan Hospital York Pennsylvania USA

3. Department of Internal Medicine Wake Forest University Winston‐Salem North Carolina USA

Abstract

AbstractIntroductionAVEIR‐VR leadless pacemaker (LP) was recently approved for clinical use. Although trial data were promising, post‐approval real world data with regard to its effectiveness and safety is lacking. To report our early experience with AVEIR‐VR LP with regard to its effectiveness and safety and compare it with MICRA‐VR.MethodsThe first 25 patients to undergo AVEIR‐VR implant at our institution between June and November 2022, were compared to 25 age‐ and sex‐matched patients who received MICRA‐VR implants.ResultsIn both groups, mean age was 73 years and 48% were women. LP implant was successful in 100% of patients in both groups. Single attempt deployment was achieved in 80% of AVEIR‐VR and 60% of MICRA‐VR recipients (p = 0.07). Fluoroscopy, implant, and procedure times were numerically longer in the AVEIR‐VR group compared to MICRA‐VR group (p > 0.05). No significant periprocedural complications were noted in both groups. Incidence of ventricular arrhythmias were higher in the AVEIR‐VR group (20%) compared to the MICRA‐VR group (0%) (p = 0.043). At 2 and 8 weeks follow‐up, device parameters remained stable in both groups with no device dislodgements. The estimated battery life at 8 weeks was significantly longer in the AVEIR‐VR group (15 years) compared to the MICRA‐VR group (8 years) (p = 0.047). With 3−4 AVEIR‐VR implants, the learning curve for successful implantation reached a steady state.ConclusionOur initial experience with AVEIR‐VR show that it has comparable effectiveness and safety to MICRA‐VR. Larger sample studies are needed to confirm our findings.

Publisher

Wiley

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3